Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
300.90B
Market cap300.90B
Price-Earnings ratio
16.85
Price-Earnings ratio16.85
Dividend yield
2.71%
Dividend yield2.71%
Average volume
8.36M
Average volume8.36M
High today
$123.32
High today$123.32
Low today
$121.08
Low today$121.08
Open price
$122.92
Open price$122.92
Volume
1.76M
Volume1.76M
52 Week high
$125.14
52 Week high$125.14
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

As of today, Merck(MRK) shares are valued at $121.71. The company's market cap stands at 300.9B, with a P/E ratio of 16.85 and a dividend yield of 2.7%.

As of 2026-04-10, Merck(MRK) stock has fluctuated between $121.08 and $123.32. The current price stands at $121.71, placing the stock +0.5% above today's low and -1.3% off the high.

The Merck(MRK)'s current trading volume is 1.76M, compared to an average daily volume of 8.36M.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $125.14 at its peak.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $125.14 at its peak.

MRK News

Simply Wall St 13h
Merck’s Lower Terns Bid Highlights Oncology Ambition And Valuation Questions

Merck (NYSE:MRK) has commenced a cash tender offer to acquire Terns Pharmaceuticals, targeting assets that expand its oncology pipeline. After reviewing newly...

Merck’s Lower Terns Bid Highlights Oncology Ambition And Valuation Questions
Simply Wall St 2d
Has Merck Already Done The Heavy Lifting After A 56% One-Year Rally?

If you are wondering whether Merck at around US$123 per share still offers value or has already done the heavy lifting, you are asking the right question. The...

Has Merck Already Done The Heavy Lifting After A 56% One-Year Rally?
The Motley Fool 2d
Why Terns Pharmaceuticals Stock Rocked the Market in March

Terns Pharmaceuticals (TERN +0.11%) had a more memorable March than a great many other companies on U.S. stock exchanges. That's largely because it agreed to be...

Why Terns Pharmaceuticals Stock Rocked the Market in March

Analyst ratings

67%

of 30 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

More MRK News

Benzinga 3d
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review

The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion. Updated Trial Data Influences Merck Negotiations During deal...

Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
TipRanks 3d
Terns Pharmaceuticals downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Terns Pharmaceuticals (TERN) to Market Perform from Outperform. Following Terns’ filing of its Schedule 14D-9 solicitation/recommendati...

24/7 Wall St. 3d
Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought?

Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought? By Trey Thoelcke Published Apr 7, 10:05AM EDT Quick Read Costco (COST) trades at...

Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought?
TipRanks 3d
Merck begins tender offer to acquire Terns Pharmaceuticals

Merck (MRK) is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals (TERN). O...

Simply Wall St 5d
Assessing Merck Valuation After Keytruda EU Approval And Strong Oral PCSK9 Phase 3 Results

Merck (MRK) is back in focus after two key milestones: strong Phase 3 data for its oral PCSK9 candidate enlicitide decanoate, and fresh EU approval expanding Ke...

Assessing Merck Valuation After Keytruda EU Approval And Strong Oral PCSK9 Phase 3 Results

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.